Table 3.
Age on diagnosis (year) | ||||||||||
---|---|---|---|---|---|---|---|---|---|---|
0–9 (N = 7) | 10–19 (N = 58) | 20–29 (N = 48) | 30–39 (N = 40) | 40–49 (N = 60) | 50–59 (N = 73) | 60–69 (N = 49) | 70–79 (N = 21) | 80–89 (N = 2) | p-value | |
Remission | 6 (86%) | 52 (90%) | 37 (77%) | 35 (88%) | 46 (77%) | 56 (77%) | 39 (80%) | 15 (71%) | 1 (50%) | 0.411 |
Incomplete response | 1 (14%) | 6 (10%) | 11 (23%) | 5 (14%) | 14 (23%) | 14 (19%) | 9 (18%) | 6 (29%) | 1 (50%) | 0.452 |
Treatment failure | 0 (0%) | 0 (0%) | 0 (0%) | 0 (0%) | 0 (0%) | 3 (4%) | 1 (2%) | 0 (0%) | 0 (0%) | 0.346a |
Time to remission (months) | 28 | 18 | 5 | 5 | 7.5 | 6 | 7 | 6 | 44 | 0.074 |
Loss of remission | 3 (50%) | 36 (71%) | 21 (60%) | 24 (69%) | 25 (56%) | 29 (52%) | 22 (56%) | 10 (100%) | 1 (60%) | 0.558 |
Relapse | 2 (33%) | 29 (56%) | 20 (56%) | 14 (40%) | 14 (31%) | 21 (38%) | 15 (39%) | 6 (40%) | 0 (0%) | 0.228 |
Side effects corticosteroids | ||||||||||
Osteoporosis | 0 (0%) | 7 (12%) | 4 (8%) | 3 (8%) | 5 (8%) | 16 (22%) | 1 (2%) | 4 (19%) | 0 (0%) | 0.035 |
Cushingoid changes | 0 (0%) | 8 (14%) | 4 (8%) | 8 (20%) | 3 (5%) | 6 (8%) | 3 (6%) | 1 (5%) | 1 (0%) | 0.239 |
Steroid induced diabetes | 1 (14%) | 2 (3%) | 2 (4%) | 2 (5%) | 2 (3%) | 6 (8%) | 8 (16%) | 4 (19%) | 0 (0%) | 0.078 |
Side effects immunomodulator | ||||||||||
Leucopenia | 1 (14%) | 6 (10%) | 2 (4%) | 1 (3%) | 0 (0%) | 3 (4%) | 3 (6%) | 0 (0%) | 0 (0%) | 0.210 |
GI-symptoms | 0 (0%) | 0 (0%) | 2 (4%) | 3 (8%) | 2 (3%) | 5 (7%) | 2 (4%) | 0 (0%) | 0 (0%) | 0.570 |
Number (percentage), Median. For calculation of percentages and statistics cases with missing values were excluded
aShould be interpreted with caution because of low numbers of events